Search

Displaying results 3491 - 3500 of 8697 in total
  1. Drug

    Cyclacillin

    go.drugbank.com/drugs/DB01000
    Approved

    A cyclohexylamido analog of penicillanic acid.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharma...

  3. Drug

    Ioxitalamic acid

    go.drugbank.com/drugs/DB13444
    ApprovedWithdrawn

    Ioxitalamate is an ionic iodinated contrast medium.[A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg.

  4. Drug

    Brotizolam

    go.drugbank.com/drugs/DB09017
    ApprovedWithdrawn

    Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. … Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Stannous chloride

    go.drugbank.com/drugs/DB11056
    Approved

    These complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue [FDA Label].

  6. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. … [L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition.

    Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 Substrates
  7. Drug

    T-5224

    go.drugbank.com/drugs/DB05998
    Experimental

    T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

  8. Drug

    PF-05212377

    go.drugbank.com/drugs/DB16044
    Investigational

    PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms

  9. Drug

    Crovalimab

    go.drugbank.com/drugs/DB16128
    ApprovedInvestigational

    [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). … [L50933] Unlike other complement inhibitors previously approved for PNH, crovalimab uses a mechanism called anti-C5 sequential monoclonal antibody recycling technology that allows the drug to bind to

  10. Drug

    Clove oil

    go.drugbank.com/drugs/DB11338
    ApprovedNutraceutical

    The antioxidant and antimicrobial activity of clove is higher than that of many fruits, vegetables, and other spices [A33133]. … The FDA categorizes clove oil as generally recognized as safe (GRAS) for use in dental cement or as a food additive [F108].